May 24, 2025 a 11:31 am
MRK: Dividend Analysis - Merck & Co., Inc.
Merck & Co., Inc. is a stable dividend-paying company with a substantial history of consistent payouts, backed by a robust market capitalization and a solid payout ratio. With a dividend yield of 3.33% and steady growth over the years, Merck presents a reliable investment opportunity for dividend-focused investors. Despite potential market fluctuations, its dividend resilience over 56 years highlights strong governance and financial management.
📊 Overview
Merck & Co., Inc. operates in the healthcare sector, providing valuable dividend returns to its shareholders.
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Dividend yield | 3.33 % |
| Current dividend per share | 3.10 USD |
| Dividend history | 56 years |
| Last cut or suspension | None |
🗣️ Dividend History
Understanding the historical dividend payments of Merck underscores its commitment to returning value to shareholders. A long unbroken history of dividends is a sign of stability and maturity in its cash flow management.
| Year | Dividend Per Share (USD) |
|---|---|
| 2025 | 0.81 |
| 2024 | 3.12 |
| 2023 | 2.96 |
| 2022 | 2.80 |
| 2021 | 2.61 |
📈 Dividend Growth
The growth of dividends over time is crucial as it indicates the company's ability to increase shareholder value through improved earnings and optimal capital allocation.
| Time | Growth |
|---|---|
| 3 years | 6.13 % |
| 5 years | 7.67 % |
The average dividend growth is 7.67 % over 5 years. This shows moderate but steady dividend growth.
✅ Payout Ratio
The payout ratio indicates the proportion of earnings paid out as dividends, a key measure to gauge dividend sustainability.
| Key figure | Ratio |
|---|---|
| EPS-based | 44.95 % |
| Free cash flow-based | 45.63 % |
With an EPS payout ratio of 44.95 % and an FCF payout ratio of 45.63 %, Merck demonstrates a balanced approach to distributing dividends, ensuring enough retained earnings for business reinvestments.
🌀 Cashflow & Capital Efficiency
Evaluating cash flow metrics and capital efficiency metrics provides insight into how well Merck manages and utilizes its financial resources.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Free Cash Flow Yield | 7.18 % | 3.22 % | 5.24 % |
| Earnings Yield | 6.80 % | 0.13 % | 5.17 % |
| CAPEX to Operating Cash Flow | 15.71 % | 29.70 % | 22.98 % |
| Stock-based Compensation to Revenue | 1.19 % | 1.07 % | 0.91 % |
| Free Cash Flow / Operating Cash Flow Ratio | 84.29 % | 70.29 % | 77.02 % |
Merck's cash flow and capital utilization reveal solid capital allocation with a robust Free Cash Flow yield, even amidst fluctuating operating conditions.
🏦 Balance Sheet & Leverage Analysis
An analysis of leverage and balance sheet health provides a clearer picture of Merck's financial stability and risk profile.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt-to-Equity | 0.80 | 0.97 | 0.67 |
| Debt-to-Assets | 31.69 % | 33.99 % | 28.12 % |
| Debt-to-Capital | 44.48 % | 49.11 % | 40.02 % |
| Net Debt to EBITDA | 0.96 | 4.26 | 0.84 |
| Current Ratio | 1.41 | 1.25 | 1.47 |
| Quick Ratio | 1.15 | 1.00 | 1.23 |
| Financial Leverage | 2.53 | 2.83 | 2.37 |
Merck maintains a prudent balance between leveraging and operational equity, ensuring stability in its debt practices.
📈 Fundamental Strength & Profitability
Key profitability ratios and margins gauge the financial performance and operational efficiency of Merck.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Return on Equity | 36.96 % | 0.97 % | 31.57 % |
| Return on Assets | 14.62 % | 0.34 % | 13.30 % |
| Margins: Net | 26.67 % | 0.61 % | 24.49 % |
| Margins: EBIT | 35.48 % | 5.05 % | 29.36 % |
| Margins: EBITDA | 41.98 % | 11.49 % | 35.95 % |
| Margins: Gross | 76.32 % | 73.17 % | 70.63 % |
| R&D to Revenue | 27.48 % | 50.79 % | 22.85 % |
Merck shows excellent operational efficiency with strong profit margins and effective utilization of its research and development spending vis-a-vis revenues.
📈 Price Development
🔍 Dividend Scoring System
| Category | Description | Score |
|---|---|---|
| Dividend yield | Returns from dividends relative to price | 4/5 |
| Dividend Stability | Consistency in dividend payments | 5/5 |
| Dividend growth | Increment in dividend payouts | 3/5 |
| Payout ratio | Portion of earnings distributed | 4/5 |
| Financial stability | Balance sheet robustness | 4/5 |
| Dividend continuity | Uninterrupted dividend flow | 5/5 |
| Cashflow Coverage | Cash flow sufficiency for dividends | 4/5 |
| Balance Sheet Quality | Consistency of financial health | 4/5 |
Overall Score: 33/40
🔚 Rating
Merck & Co., Inc. maintains a solid position as a reliable and stable income-generating stock, meriting a strong investment consideration. With consistent dividend growth and robust fundamentals, it ensures sustained investor confidence.